News By Tag
News By Location
Gastrointestinal Disorders Therapeutics Market to 2018
Researchers Bust a Gut to Improve Gastrointestinal Disorders Market
Drugs to treat gastrointestinal disorders are due to see a significant price drop, as patents run out and research takes off, according to a new report by healthcare experts.
The new report* states that patients with disorders such as Irritable Bowel Syndrome (IBS), Crohn’s disease, Ulcerative Colitis (UC), Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD) will experience a rush in new generic versions of popular medication, and new novel drugs with the hope of better results.
The market for gastrointestinal disorder therapeutics is being driven by increased stress, unhealthy eating habits, the growth of the global elderly population and an increased level of awareness among the general population, which has spurred on the rise of incidence and diagnosis over the recent past. Anxiety, unhealthy foods and advanced age can all be associated with changes in gastrointestinal physiology. However, gastrointestinal diseases still have a low diagnosis rate, and a fear of serious side effects may restrain market growth.
The gastrointestinal disorders therapeutics market is set to experience strong generic competition during the forecast period, as several major branded drugs used in to treat gastrointestinal disorders are set to expire during 2011-2015, including Nexium (esomeprazole magnesium), Aciphex (rabeprazole sodium), Tysabri (natalizumab)
For Sample Pages, please click or add the below link to your browser:
However the market is set to witness a steady growth from 2015 onwards due to the anticipated entry of innovative new drugs, as the industry shows strong R&D activity in IBS, constipation, Crohn’s disease and UC with effective and novel drug molecules. There are approximately 269 ongoing clinical trials in the gastrointestinal disorders therapeutics market, with the main focus being on Crohn’s disease and UC. 42% of all ongoing clinical trials are in Phase II and 22% are in the late stages (Phase III and NDA-filed). This robust pipeline increases the chance of getting new drugs to market and may represent better treatment options with fewer side effects.
The Irritable Bowel Syndrome (IBS) and constipation therapeutics markets were valued at $722m and $1.7 billion in 2011, and are expected to grow at CAGRs of 13.7% and 11.1% to $1.8 billion and $3.6 billion respectively in 2018. This high growth rate is attributed to the strong pipeline dominated by First-In-Class (FIC) molecules such as recently launched Linzess (linaclotide)
This report provides in-depth analysis of the major gastrointestinal diseases, comprising IBS, constipation, Crohn’s disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). It gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and codevelopment deals that have taken place in the past two years.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782